BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice

Journal of Investigative Dermatology

Volumn 127, Issue 12, 2007, Pages 2772-2780

  Matsushita, Takashi ^a   Fujimoto, Manabu ^a   Hasegawa, Minoru ^a   Matsushita, Yukiyo ^a   Komura, Kazuhiro ^a   Ogawa, Fumihide ^b   Watanabe, Rei ^c   Takehara, Kazuhiko ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BAFF ANTAGONIST; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; DISEASE COURSE; DOWN REGULATION; DRUG INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SURVIVAL; UPREGULATION;

EID: 36248941233     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700919     Document Type: Article

References (63)

1. Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H et al. (2004) B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165:641-50
2. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253-65
3. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J et al. (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192:1453-66
4. Bhogal RK, Stoica CM, McGaha TL, Bona CA (2005) Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol 25:592-603
5. Bocchieri MH, Christner PJ, Henriksen PD, Jimenez SA (1993) Immunological characterization of (tight skin/NZB)F1 hybrid mice with connective tissue and autoimmune features resembling human systemic sclerosis. J Autoimmun 6:337-51
6. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-9
7. Dodig TD, Mack KT, Cassarino DF, Clark SH (2001) Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 44:723-7
8. Duncan MR, Berman B (1991) Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97:686-92
9. Engel P, Zhou L-J, Ord DC, Sato S, Koller B, Tedder TF (1995) Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3:39-50
10. Everett ET, Pablos JL, Harley RA, LeRoy EC, Norris JS (1995) The role of mast cells in the development of skin fibrosis in tight-skin mutant mice. Comp Biochem Physiol 110A:159-65
11. Famularo G, Giacomelli R, Alesse E, Cifone MG, Morrone S, Boirivant M et al. (1989) Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 29:59-63
12. Fleischmajer R, Perlish JS, Reeves JRT (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975-84
13. Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W et al. (2003) Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 48(Suppl):S377
14. Green MC, Sweet HO, Bunker LE (1976) Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82:493-512
15. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P et al. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109:59-68
16. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15:289-302
17. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-9
18. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M et al. (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954-66
19. Hatakeyama A, Kasturi KN, Wolf I, Phelps RG, Bona CA (1996) Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Cell Immunol 167:135-40
20. Jiang Y, Ohtsuji M, Abe M, Li N, Xiu Y,Wen S et al. (2001) Polymorphism and chromosomal mapping of the mouse gene for B-cell activating factor belonging to the tumor necrosis factor family (Baff) and association with the autoimmune phenotype. Immunogenetics 53:810-3
21. Jimenez SA, Williams CJ, Myers JC, Bashey RI (1986) Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 261:657-62
22. Kasturi KN, Hatakeyama A, Murai C, Gordon R, Phelps RG, Bona CA (1997) B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J Autoimmun 10:505-17
23. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17:515-24
24. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I et al. (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97:3370-5
25. Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA (2002) Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 99:3800-5
26. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M (1993) Antoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91:1399-404
27. Lemaire R, Bayle J, Lafyatis R (2006) Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-beta regulation and systemic sclerosis. Curr Opin Rheumatol 18:582-7
28. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al. (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202-5
29. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-6
30. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465-75
31. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-710
32. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192-201
33. Mauri C, Gray D, Mushtaq N, Londei M (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197:489-501
34. McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE et al. (2001) Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4ralpha and transforming growth factor-beta genes. J Invest Dermatol 116:136-43
35. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J (2001) A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 3:55-61
36. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-3
37. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199:91-8
38. Ong CJ, Ip S, Teh SJ, Wong C, Jirik FR, Grusby MJ et al. (1999) A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 196:60-8
39. Osborn TG, Bauer NE, Ross SC, Moore TL, Zucker J (1983) The tight-skin mouse: physical and biochemical properties of the skin. J Rheumatol 10:793-6
40. Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA (1993) Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6Pa/Pa mice. J Autoimmun 6:701-18
41. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H et al. (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116:724-34
42. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y et al. (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453-62
43. Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis. Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918-27
44. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang MLK et al. (1996) CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5:551-62
45. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111-4
46. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-56
47. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S et al. (2001) Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 194:1691-7
48. Shen Y, Ichino M, Nakazawa M, Minami M (2005) CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol 124:1141-8
49. Siracusa LD, McGrath R, Fisher JK, Jimenez SA (1998) The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome 9:907-9
50. Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ et al. (1996) A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6:300
51. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203
52. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D et al. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48:3475-86
53. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H et al. (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163:1066-72
54. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F et al. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785-98
55. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108-11
56. Tsuji-Yamada J, Nakazawa M, Takahashi K, Iijima K, Hattori S, Okuda K et al. (2001) Effect of IL-12 encoding plasmid administration on tight-skin mouse. Biochem Biophys Res Commun 280:707-12
57. Walker MA, Harley RA, DeLustro FA, LeRoy EC (1989) Adoptive transfer of Tsk skin fibrosis to +/+ recipients by Tsk bone marrow and spleen cells. Proc Soc Exp Biol Med 192:196-200
58. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT et al. (2006) Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 54(Suppl):S790
59. Wallace VA, Kondo S, Kono T, Xing Z, Timms E, Furlonger C et al. (1994) A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 24:1463-6
60. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L et al. (2001) TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2:632-7
61. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A et al. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319-24
62. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10
63. Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype". J Immunol 175:4555-60